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Abstract 
Background: In contrast to rat and mouse databases, the NCBI gene database lists the human dual‑endothelin1/
VEGFsp receptor (DEspR, formerly Dear) as a unitary transcribed pseudogene due to a stop [TGA]‑codon at codon#14 
in automated DNA and RNA sequences. However, re‑analysis is needed given prior single gene studies detected a 
tryptophan [TGG]‑codon#14 by manual Sanger sequencing, demonstrated DEspR translatability and functionality, 
and since the demonstration of actual non‑translatability through expression studies, the standard‑of‑excellence for 
pseudogene designation, has not been performed. Re‑analysis must meet UNIPROT criteria for demonstration of a 
protein’s existence at the highest (protein) level, which a priori, would override DNA‑ or RNA‑based deductions.
Methods: To dissect the nucleotide sequence discrepancy, we performed Maxam–Gilbert sequencing and reviewed 
727 RNA‑seq entries. To comply with the highest level multiple UNIPROT criteria for determining DEspR’s existence, 
we performed various experiments using multiple anti‑DEspR monoclonal antibodies (mAbs) targeting distinct DEspR 
epitopes with one spanning the contested tryptophan [TGG]‑codon#14, assessing: (a) DEspR protein expression, (b) 
predicted full‑length protein size, (c) sequence‑predicted protein‑specific properties beyond codon#14: receptor gly‑
cosylation and internalization, (d) protein‑partner interactions, and (e) DEspR functionality via DEspR‑inhibition effects.
Results: Maxam–Gilbert sequencing and some RNA‑seq entries demonstrate two guanines, hence a tryptophan 
[TGG]‑codon#14 within a compression site spanning an error‑prone compression sequence motif. Western blot 
analysis using anti‑DEspR mAbs targeting distinct DEspR epitopes detect the identical glycosylated 17.5 kDa pull‑
down protein. Decrease in DEspR‑protein size after PNGase‑F digest demonstrates post‑translational glycosylation, 
concordant with the consensus‑glycosylation site beyond codon#14. Like other small single‑transmembrane proteins, 
mass spectrometry analysis of anti‑DEspR mAb pull‑down proteins do not detect DEspR, but detect DEspR‑protein 
interactions with proteins implicated in intracellular trafficking and cancer. FACS analyses also detect DEspR‑protein 
in different human cancer stem‑like cells (CSCs). DEspR‑inhibition studies identify DEspR‑roles in CSC survival and 
growth. Live cell imaging detects fluorescently‑labeled anti‑DEspR mAb targeted‑receptor internalization, concordant 
with the single internalization‑recognition sequence also located beyond codon#14.
Conclusions: Data confirm translatability of DEspR, the full‑length DEspR protein beyond codon#14, and elucidate 
DEspR‑specific functionality. Along with detection of the tryptophan [TGG]‑codon#14 within an error‑prone compres‑
sion site, cumulative data demonstrating DEspR protein existence fulfill multiple UNIPROT criteria, thus refuting its 
pseudogene designation.
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Background
In contrast to rat and mouse databases listing Dear as a 
gene, DNA and RNA sequence databases list the human 
Dear gene or the dual-endothelin1/VEGFsp receptor 
(DEspR) as a pseudogene [1] (Additional file  1: Figure 
S1). Automated DNA sequence databases report a stop 
codon [TGA] instead of tryptophan [TGG] at codon#14 
reported in single gene study [2]. The current NCBI 
pseudogene annotation updated in May 2016 and refer-
enced in other sites is discrepant with the single research 
group single-gene studies of human DEspR showing 
expression in human kidney via immunohistochemistry 
using a polyclonal anti-DEspR antibody, and functional 
studies of human DEspR expressed in permanent Cos1 
cell transfectants detecting the predicted protein size by 
Western blot analysis as well as binding to DEspR-ligands 
(endothelin-1 and VEGFsp) [2]. The NCBI pseudogene 
annotation is also discrepant with the single gene study 
demonstrating DEspR-specific functional roles in cancer 
and putative regulation at the splicing level with detec-
tion of both unspliced and spliced DEspR RNA in human 
tumor cells by allele-specific amplification-refractory 
mutation system (ARMS) methodology [3].
Experimental clarification is warranted since the basis 
for the NCBI pseudogene annotation, automated DNA/
RNA-sequencing, is known to have reproducible sys-
tematic sequencing errors, regardless of technology [4]. 
Occurrences of, hence risks for, systematic errors elimi-
nate the a priori assumption that multiple occurrences 
negate errors. More specifically, systematic errors in 
high throughput DNA sequencing has been observed to 
occur “even in overlapping paired reads from high-cov-
erage data, approximately one in 1000 bp, and are highly 
replicable across experiments” [4]. Moreover, given dis-
crepancies among methodologies, the Sanger sequencing 
is the final determinant of sequence discrepancy since 
“any difference from the Sanger sequence is defined as a 
sequencing error” [5].
Further support for the need for scientific clarification 
is found in the GENCODE Pseudogene Resource which 
states that “the definition of a pseudogene is based on 
the presence of specific characteristics such as premature 
stop codon, coding sequence frame shift, truncation, or 
disabling insertion/deletion—unless evidence (transcrip-
tional, functional, publication) shows that the locus rep-
resents a protein-coding gene” [6]. Concordant with Pei 
et al. [6], Kageyama et al. [7] explicitly states that “before a 
particular transcript can be determined to be a long non-
coding RNA (or ‘transcribed pseudogene’), there must be 
somewhat convincing evidence for its lack of translatabil-
ity.” Hence, deductions from automated sequence data-
bases need to be evaluated in the context of experimental 
evidence for translatability and functionality.
To address the need for scientific clarification of DEspR 
(Dear) as a gene or pseudogene, we therefore upheld 
established standards that (1) “the translatability of 
the candidate can be validated with specific antibodies 
against amino acid sequences predicted from the ORF,” 
[7] and that (2) “an assessment of … a protein’s molecular 
activity by biochemical methods should be the final certi-
fication of an active gene product” [7]. These perspectives 
are codified in the Central Protein Resource UNIPROT 
criteria for translatability: “evidence for existence of a 
protein at the protein level, such as via antibody detec-
tion, is the highest level of evidence” [8].
Here we confirm the existence of the DEspR gene prod-
uct at the nucleotide and protein level. We show that 
both Sanger and Maxam–Gilbert sequencing detect two 
G’s for a tryptophan [TGG]-codon#14. We also deter-
mine that some RNA-seq entries also contain two G’s but 
with an extra A or TA, as the region in question spans 
a canonical Yamakawa compression motif [9]. Monoclo-
nal anti-DEspR antibodies to different DEspR epitopes 
detect the identical glycosylated 17.5 kDa pull-down pro-
tein from membrane-bound proteins from human tumor 
cells and the Cos1-DEspR  +  permanent transfectants 
cells. More importantly, DEspR molecular activity, pro-
tein–protein interactions, protein-specific properties and 
functionality are shown, and found to play key roles in 
cancer stem cell anoikis resistance and growth.
Results
Confirmation of two G’s and compression site
To determine whether the two G’s are detected form-
ing tryptophan [TGG]-codon#14, as observed in Sanger 
sequencing (Additional file  2: Figure S2), we performed 
manual Maxam–Gilbert sequencing using 8  % denatur-
ing polyacrylamide sequencing gels on 32P end-labeled 
PCR-amplified cDNA electrophoresed at three differ-
ent fixed wattages (Fig. 1a). Clearly, the two G’s are noted 
with the corresponding C bands that accompany most 
G nucleotides. Interestingly, the compression in the gel 
run is consistently observed in Sanger sequencing and in 
Maxam–Gilbert sequencing, and contains the compres-
sion motif found in 68 % of sequencing errors with com-
pression [9] (Fig.  1a; Additional file  2: Figure S2). This 
compression results in the “slippage’ of the two G’s with 
a T nucleotide, thus leaving a space in the gel read. Addi-
tionally, the compression region is within a 3-nt stem-loop 
structure that could render this region prone to sequenc-
ing errors which are not present in rat and mouse DEspR 
gene sequences, both of which also contain the identical 
tryptophan [TGG]-codon#14 (Additional file 2: Figure S2).
Importantly, queries against subsets of the NCBI 
sequence read archive (SRA) database reveals DEspR-spe-
cific exon sequences which would not be expected for the 
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FBXW7 transcript in the opposite strand (Fig. 1b). Nota-
bly, five entries show the two G’s out of 124 data entries in 
said file (Additional file 3: Figure S3), and that these two 
G’s are associated with an insertion of a “T–A’ or an “A” 
(Additional file 3: Figure S3). These observations show that 
the two G’s are indeed detected and are located within a 
problematic sequencing region, concordant with observa-
tions in manual sequencing gels of nucleotide compres-
sion spanning a known sequence motif for compression 
[9]. These data show the questioned two G’s in support of 
tryptophan [TGG] codon in 5/124 sequences similar to 
manual sequencing runs. Given that Sanger-sequencing 
is the accepted standard final determinant of nucleotide 
discrepancies [5], these experimental data support the 
need for clarification and demonstration of DEspR protein 
expression.
Analysis of translatability and protein‑specific properties
In order to clarify the existence of DEspR protein com-
plying with established UNIPROT criteria for detection 
of protein by antibody made from deduced amino acid 
sequences, we performed anti-DEspR mAb pull-down 
and subsequent Western blot and mass spectrometry 
analyses of pull-down products from cell membranes. 
Membranes were isolated from human glioblastoma 
tumor cells and U87 cancer stem-like cells (CSC) which 
we isolated and characterized for CSC tumor initiating 
properties [3]. We performed pull-down experiments 
using an anti-human DEspR specific antibody, 5g12e8 
mAb (Fig. 2a), which detected DEspR on prior Western 
blot analysis of CSC membrane proteins [3].
Analysis of pull-down products by mass spectrom-
etry (MS) (Table  1; Additional file  4: Table S1) revealed 
that the DEspR-protein interacts with several proteins 
involved in intracellular trafficking, angiogenesis, and/or 
cancer: vimentin, Gal-3, Gal-1 and TMED10. Although 
MS analyses did not detect DEspR (Table 1), Western blot 
analyses of pull-down products detected DEspR protein 
bands at  ~17.5 and  ~12.5  kDa, larger than the deduced 
amino acid sequence predicting  ~10  kDa, and distinct 
from the other proteins in the pull-down-complex: Rab-
1b (22 kDa), Galectin-1 (14 kDa) and TMED10 (25 kDa) 
(Fig. 2b). Data indicate that DEspR is likely glycosylated 
given its consensus glycosylation site [N-F-S-G] (Fig. 2a), 
and clearly distinct from the other proteins in the pull-
down complex as evidenced by size, relative abundance, 
and the lack of antibody cross-reactivity (Fig.  2b). Gly-
cosylation of DEspR is confirmed after peptide-N-gly-
cosidase F (PNGase F) treatment of pull-down proteins 
showing decrease in size of DEspR upon Western blot 
Fig. 1 DEspR DNA and RNA sequence analysis. a Maxam–Gilbert DNA nucleotide sequence analysis in three different gel runs of increasing 
wattage (#1 = 25 watts; #2 = 35 watts; #3 = 50 watts) spanning controversial region shows: consistent area of compression (}) which contains the 
Yamakawa compression‑motif. The compressed two G’s and single T are depicted in codon#14: TGG.], codons; the two G’s (in red). b Representa‑
tive RNA‑Seq analysis of 727 unedited RNA‑seq entries show DEspR exon‑specific RNAs distinguished from the anti‑sense strand transcript, FBXW7, 
exon‑specific sequence. Query DEspR sequence spans 1–372 nt of DEspR transcript
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Fig. 2 Analysis of DEspR translatability. a Schematic diagram of DEspR protein and mAb‑epitopes. Two distinct peptides (epitope‑1, epitope‑2) in the 
extracellular domain were used to develop murine monoclonal antibodies (mAbs). Two high‑affinity mAbs target human‑specific epitope‑1: 7c5b2, 
5g12e8; and one high‑affinity mAb targets the pan‑species reactive epitope‑2, identical in human, monkey, and rat. Epitope‑2 spans the putative 
ligand binding domain [24]. The 5g12e8 mAb was used in pull‑down experiments; 5g12e8 and 6g8g7 were used in Western blot analyses, 7c5b2 
mAb was used in FACs analysis, immunostaining, and internalization assays, and all three were used in functional inhibition assays. The contested 
tryptophan (W)‑aa#14 (red); consensus glycosylation site sequence: (green, N‑F‑S‑G), known internalization recognition sequence: (blue: T‑D‑V‑P). 
A blue arrow marks the splice junction between exon1 and exon2, i.e. between amino‑acids G and K (aa#5‑#6). b Sequential Western blot analyses 
of pull‑down proteins from glioblastoma U87 membrane proteins using different antibodies specific for proteins identified by mass spectrometry 
analysis of pull‑down protein‑products. The identical blot was sequentially probed, stripped of antibody, confirmed as stripped, then re‑probed in 
the following order: #1: anti‑hDEspR‑5g12e8 mouse mAb, #2: anti‑Rab1b rabbit polyclonal Ab (pAb), #3: anti‑Galectin‑1 rabbit pAb; #4: anti‑TMED10 
rabbit pAb. Molecular weight markers are noted. DEspR bands are ~17.5 and 12.5 kDa. Expected sizes are detected for Rab1b: 22 kDa, Galectin‑1: 
14 kDa, and TMED10: 25 kDa. c Panel‑1 shows silver‑stained gel of pull‑down protein products using 5g12e8 mAb from membrane proteins isolated 
from: (1) glioblastoma U87 CSCs, (2) PNGase‑digested sample of pull‑down proteins from U87 CSCs, (3) permanent transfectants DEspR‑positive 
Cos1‑cells. Panel‑2 shows Western blot analysis using anti‑DEspR 5g12e8 mAb showing DEspR band (lane 1), smaller DEspR + band after PNGase 
digest‑samples (lane 2), and identically‑sized DEspR band in DEspR‑positive Cos1‑cell permanent transfectants showing appropriate splicing and 
translatability of DEspR‑minigene transfected into Cos‑1 cells (lane 3). Panel‑3 Western blot analysis of different wells in the same gel run probed 
with anti‑Galectin‑1 pAb showing distinct sized protein bands, thus confirming DEspR‑specific bands are not Galectin‑1 protein bands, and that 
Galectin‑1 is not glycosylated as reported. d Western blot analysis of Galectin‑1 recombinant protein. Panel 1 overlay of gel‑image and western blot 
image showing detection of Galectin‑1 recombinant protein at expected size 14 kDa. Panel 2 overlay of gel‑image and western blot image probed 
with anti‑DEspR 5g12e8 mAb showing non‑cross reactivity of anti‑hDEspR mAb with Galectin‑1. e Sequential western blot analysis of 5g12e8‑
pull‑down proteins from U87 CSCs probed first with 6g8g7 (left panel), and subsequently with 5g12e8 after ‘stripping’ (right panel), detects identical 
protein bands. This confirms that 6g8g7 epitope is on the same protein as 5g12e8 epitope, thus corroborating DEspR protein existence
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analysis (Fig. 2c, middle panel, lane 2). These data validate 
the canonical glycosylation site beyond the purported 
pseudogene stop codon#14, and provides a mechanism 
for DEspR-Galectin-1 and DEspR-Galectin-3 binding as 
observed in the pull-down products.
However, because of the abundance of Galectin-1 in 
the pull-down products, we performed more Western 
blot analyses to eliminate the possibility that anti-DEspR 
antibody cross reacts with Galectin-1 and vice versa. As 
shown in Fig.  2c, the anti-human DEspR 5g12e8 mAb 
detects the 17.5  kDa glycosylated DEspR in the pull-
down products from U87-CSC cell membrane proteins 
and from the membrane proteins isolated from DEspR-
positive Cos1-permanent transfectant cells. These 
DEspR + Cos1-permanent transfectants cells were previ-
ously shown to express human DEspR by immunostain-
ing, and to competitively bind ligands and anti-DEspR 
(7c5b2) mAb [2]. After PNGase F digestion, 5g12e8 
also detected the smaller, hence deglycosylated DEspR 
(Fig. 2c, middle panel). In contrast, anti-Galectin-1 mAb 
detected a 14  kDa protein band with markedly differ-
ent size and expression levels to DEspR in all three lanes 
(Fig. 2c, right panel).
To further confirm this distinction, we performed dou-
ble Western blot analyses of Galectin-1 recombinant pro-
tein. As shown in Fig. 2d, anti-Galectin-1 mAb detected 
human Galectin-1, in contrast to the anti-human DEspR 
5g12e8 mAb which did not cross react to both 100 and 
500  ng of purified recombinant human Galectin-1 on 
Western blot analysis, thus confirming that DEspR in 
the pull-down product is distinct from other pull-down 
products (Fig.  2b) especially Galectin-1 (Fig.  2c). Addi-
tionally, since Galectin-1 is known not to be glycosylated 
[10] as confirmed in Fig. 2c, the PNGase F-treated sam-
ple showing a decrease in size cannot, therefore, be 
Galectin-1.
To further corroborate the detection of human DEspR 
protein in human tumor cells, we performed sequential 
probing of the identical Western blot with two different 
anti-human DEspR mAbs targeting different epitopes. 
As shown in Fig. 2e, the 6g8g7 mAb targeting the epitope 
spanning the disputed tryptophan [TGG]-codon#14 
(Fig. 2a) detects both the glycosylated 17.5 kDa and the 
less glycosylated 12.5  kDa DEspR bands. After removal 
of the 6g8g7 antibody and demonstration of no residual 
signals, the Western blot was re-probed with the 5g12e8 
mAb used in the pull-down experiment and which tar-
gets a human DEspR-specific epitope spanning a peptide 
present only if correctly spliced (Fig.  2a). This 5g12e8 
probed western blot detected the identical protein bands 
(Fig.  2e), thus showing that two different anti-hDEspR 
mAbs 6g8g7 and 5g12e8, which target different epitopes, 
Table 1 Proteins pulled-down with anti-DEspR mAb 5g12e8 from U87 CSC membranes
Proteins in italic face letters are proteins detected in three independent pull-down experiments
% the percentage of the protein sequence covered by identified peptides; #SM the number of peptide spectrum matches; #P the total number of distinct peptide 
sequences identified in the protein group; #AAs number of amino acids; Mass, mass in Daltons; Score, the sum of the ion scores of all peptides that were identified
a Proteins verified by Western blot analysis of pull-down proteins; Rab-1b was detected in two independent experiments and verified by Western blot analysis 
(Fig. 2b)
Accession % #SM #P #AAs Mass Score Description
P08670 55.8 36 31 466 53,619 177.59 Vimentin (VIM)
P60709 34.4 11 9 375 41,709 66.79 Actin, cytoplasmic 1 (ACTB)
P68371 41.6 13 12 445 49,799 56.53 Tubulin beta‑4B chain (TUBB4B)
P07437 35.1 11 10 444 49,638 47.84 Tubulin beta chain (TUBB)
Q13885 29.0 10 9 445 49,874 42.11 Tubulin beta‑2A chain (TUBB2A)
P17931 25.6 7 5 250 26,136 39.26 Galectin‑3 (LGALS3)
P09382 49.6 7 6 135 14,706 38.90 Galectin-1 (LGALS1)a
Q13509 25.6 8 8 450 50,400 32.86 Tubulin beta‑3 chain (TUBB3)
Q9BUF5 15.7 6 5 446 49,825 21.46 Tubulin beta‑6 chain (TUBB6)
P61006 13.0 2 2 207 23,653 12.01 Ras‑related protein Rab‑8A (RAB8A)
C9J8S3 15.0 2 2 160 18,015 11.01 Ras-related protein Rab-7a (RAB7A)
P61026 6.0 1 1 200 22,526 9.59 Ras-related protein Rab-10 (RAB10)
P51153 5.9 1 1 203 22,759 7.60 Ras‑related protein Rab‑13 (RAB13)
H0YNE9 6.4 1 1 188 21,854 7.51 Ras‑related protein Rab‑8B (Fragment) (RAB8B)
G3V2K7 7.2 1 1 153 16,893 5.96 Transmembrane emp24 domain-containing protein 10 (TMED10)a
Q9Y3B3‑2 5.3 1 1 188 21,219 4.85 Transmembrane emp24 domain‑containing protein 7 (TMED7)
Q9BVK6 3.8 1 1 235 27,260 4.36 Transmembrane emp24 domain‑containing protein 9 (TMED9)
F8WBC0 34.4 1 1 32 3501 2.90 Ras-related protein Rap-1b (Fragment) (RAP1B)
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detect the same protein bands representing spliced and 
glycosylated DEspR.
Protein–protein interactions: analysis of co‑localization 
of DEspR and Galectin‑1
Since both DEspR and Galectin-1 are “pulled-down” con-
sistently (n =  6), we next determined whether they are 
co-localized in tumors. We performed double immu-
nostaining of xenograft tumors derived from U87-CSCs 
[3] using human specific anti-human DEspR mAb 7c5b2 
and human-specific anti-Galectin-1 antibody. As shown 
in Fig. 3a, DEspR and Galectin-1 are indeed co-localized 
in tumors, and located more in the expanding tumor 
zone. Additionally, as shown in Fig. 3b, DEspR and Galec-
tin-1 are co-expressed in tumor cells that have invaded 
through the xenograft tumor cap and adhered onto a 
microvessel in the surrounding subcutaneous tissue of 
the host nude rat. The detection of co-localization is con-
cordant with the pull-down of both DEspR and Galec-
tin-1 in multiple independent experiments (Table 1).
Analysis of functionality at multiple levels certifies DEspR 
protein
While we showed DEspR functionality in human tumor 
cells by showing that DEspR inhibition via the 7c5b2 mAb 
inhibited angiogenesis, tumor growth and invasiveness [3], 
the NCBI pseudogene designation persists (updated in May 
2016). In addition to manual nucleotide DNA sequencing 
(Fig.  1a; Additional file  2: Figure S2), review of RNA-Seq 
sequence entries (Fig. 1b; Additional file 3: Figure S3), and 
detection of DEspR translatability or expression (Figs.  2, 
3), to provide further evidence against the pseudogene 
designation, we further studied DEspR functionality since 
demonstration of functionality of a protein certifies that 
protein’s existence [7]. To ascertain functionality, we used 
different anti-human DEspR mAbs whose epitopes are 
depicted in Fig. 2a: 7c5b2, 5g12e8 and 6g8g7 (Fig. 4), and 
tested for DEspR in different cancer tissue types.
As shown in Fig. 4, we studied DEspR-inhibition effects 
on anoikis resistant cancer stem-like cells (CSCs) iso-
lated from human U87 glioblastoma tumor cell line [3], 
human MDA-MB-231 triple negative breast cancer cell 
line, human H460 non-small cell lung cancer cell line 
and human Panc1 pancreatic ductal adenocarcinoma 
cell line [3]. To first demonstrate that DEspR protein is 
expressed on the different CSCs, we performed FACS 
analysis using AF568-fluorescently labeled 7c5b2 anti-
DEspR mAb (Fig.  2a). Figure  4a shows that, compared 
to isotype control, fluorescently labeled 7c5b2-mAb spe-
cifically detected DEspR on the cell membrane in ~50 % 
of U87-CSCs, ~60 % of MB-231-CSCs, ~71 % of H460-
CSCs and ≥55 % of Panc1-CSCs in the suspension cul-
ture conditions used.
To demonstrate the functionality of DEspR proteins 
present on the cell membrane, in  vitro inhibition stud-
ies were performed using the 7c5b2, 5g12e8 and 6g8g7 
anti-human DEspR mAbs which target different DEspR 
epitopes (Fig.  2a). As shown in Fig.  4b, all three mAbs 
significantly inhibited CSC growth in the four cancer 
tissue type-CSCs tested (P  <  0.0001, One Way ANOVA 
with Tukey’s multiple comparisons test), in contrast to 
non-treated contemporaneous controls respectively. We 
note that CSC growth is representative of survival in sus-
pension culture, proliferation and ability to form stem-
cell like spheroids in suspension culture conditions. We 
also note some variations in the inhibition of CSC growth 
in vitro by the different mAbs, with 7c5b2 an 6g8g7 per-
forming better than 5g12e8 (Fig.  4), but that all mAbs 
significantly inhibit survival, proliferation, and spheroid 
formation (CSC-growth) of U87-CSCs, MDA-MB-231-
CSCs, H460-CSCs and Panc1-CSCs.
To further demonstrate DEspR functionality, we per-
formed live-cell imaging of Panc1 cells using AF568-
fluorescently labeled 7c5b2 mAb (Fig. 5) given the single 
consensus internalization-recognition sequence [T-D-
V-P] in the deduced DEspR amino acid protein located 
beyond the contested stop codon vs amino acid #14-W 
(Fig. 2a). Demonstration of internalization would indicate 
translation and expression of the DEspR protein beyond 
the purported [TGA] stop codon#14, thus refuting the 
presence of the stop codon. As shown in Fig.  5a, time 
series of live-cell imaging shows increasing amounts of 
intracellular internalization beginning around 15–30 min 
and incrementally increasing up to 75 min after addition 
of fluorescent 7c5b2 anti-DEspR mAb. Higher magnifi-
cation confirms intracellular fluorescence accumulation 
with fluorescently labeled 7c5b2 but not with isotype 
control IgG2b-AF568 (Fig.  5b), thus indicating AF568-
labeled 7c5b2-DEspR-mediated internalization rather 
than non-specific endocytosis. Demonstration of inter-
nalization affirms DEspR protein functionality, and fur-
ther refutes the presence of the stop codon.
Discussion
Stop [TGA] codon vs tryptophan [TGG] codon within a 
sequence‑compression region
The detection of the two G’s to make tryptophan [TGG]-
codon#14 in manual sequencing Sanger-dideoxy sequenc-
ing and Maxam and Gilbert sequencing, along with 
confirmation of sequence compression at the site within 
a Yamakawa compression-motif whether sequencing the 
sense strand (Maxam–Gilbert) or the antisense strand 
(Sanger dideoxy sequence), strongly suggests that the 
NCBI designation of human Dear/DEspR as a pseudo-
gene based on stop codon#14 is erroneous. Following the 
accepted standard that manual Sanger sequencing defines 
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the correct sequence rather than the automated sequence, 
the single gene analysis data indicates that the TGG codon 
is present rather than the TGA stop codon reported in 
automated DNA sequencing databases. This interpreta-
tion is supported by the fact that systematic sequencing 
errors are documented to occur with both position- and 
sequence-specificity even in “next generation sequencing 
technologies at rates greater than prior technologies” [4]. 
Existence of the tryptophan[TGG]-codon#14 is indepen-
dently supported by detection of the DEspR protein by 
mAbs 5g12e8 and 7c5b2 whose peptide epitopes exist only 
if the DEspR RNA is spliced, and in the case of 6g8g7, only 
if the contested tryptophan[TGG]-codon#14 is present 
(Fig.  2a). Notably, 5g12e8 and 6g8g7 detect DEspR-pro-
tein as a glycosylated 12.5–17.5  kDa protein band, much 
greater than the 1.5 kDa predicted from a 13 amino acid 
peptide should there be a stop codon at codon#14. Fur-
thermore, functional validation of the glycosylation and 
internalization recognition sequences beyond codon#14 
(Figs. 2, 5) experimentally refute a stop codon at codon#14.
Fig. 3 Dual‑fluorescence co‑immunostaining analysis of DEspR and Galectin‑1 expression. a Analysis of the expanding tumor zone of a U87‑CSC 
xenograft tumor invading through the tumor fibrous cap. Co‑localization (yellow, yellow dotted circle) of increased human‑DEspR expression (red dot-
ted circle) in invasive U87 tumor cells and Galectin‑1 (green dotted circle) is observed in the invasive front. {}, invasive tumor front. Host subcutaneous 
tissue is to the upper right corner. b Co‑localization of hDEspR and Galectin‑1 is detected in tumor cells adhering to the outer wall of a microvessel in 
the subcutaneous tissue demonstrating invasive nature of U87 in xenograft tumors and homing to microvessels
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Insights regarding other high throughput database reports
The non-detection of DEspR sequences in normal human 
tissue RNA-Seq databases is unsurprising since DEspR is 
not expressed or minimally expressed in normal tissues. 
Moreover, detection of unspliced DEspR-specific RNA 
as the dominant species [3] does not indicate non-trans-
lation, since regulation at the splicing level has recently 
been described for granulocyte differentiation whereby 
the dominant RNA species in the cell is the unspliced 
form [11, 12], similar to observations for detection of 
both spliced and unspliced DEspR-transcripts by ARMS-
PCR [3].
Moreover, since DEspR overlaps with a larger tran-
script, FBXW7, on the opposite strand [3], RNA-seq 
databases that specifically exclude double stranded 
DNA [13] will also exclude RNA–RNA sequences such 
as DEspR-FBXW7 hybrids. The process-exclusion of 
RNA–RNA hybrids in RNA-Seq entries in current meth-
odologies is due to the standard of excellence requiring 
elimination of all double stranded DNA in RNA-Seq 
libraries [13], which inadvertently will also exclude RNA–
RNA hybrids. More specifically, since RNA–RNA hybrids 
can form in standard RNA isolation methods with phe-
nol extraction [14], and can form during RNA-seq library 
preparation using primer annealing reactions at tempera-
tures lower than the melting temperatures (Tm) of RNA–
RNA hybrids, and given process-exclusion of any dsDNA 
or RNA–RNA or dsDNA-RNA hybrids, there is an inad-
vertent bias introduced against the detection of DEspR-
specific transcripts due to RNA–RNA hybrids formed 
between DEspR transcript and exon#5 (or #6 depend-
ing on dataset numbering) of FBXW7 transcript on the 
opposite strand.
In parallel, the non-detection in proteomic databases 
is concordant with difficulties in detecting membrane 
proteins with single transmembrane domains that are 
less than 150  kDa [15], especially if glycosylated, since 
PNGase F treatments do not necessarily ensure detec-
tion by MS [16]. The current non-detection of DEspR 
transcripts in transcriptomics could also be due to the 
exclusion of RNA–RNA hybrids, and in primer pair-spe-
cific amplification due to the absence of DEspR-specific 
primers given the non-recognition of the DEspR gene by 
NCBI.
Confirmation of translatability
Demonstration of translatability through different exper-
imental designs and using anti-human-DEspR mAbs 
Fig. 4 Demonstration of DEspR protein and functionality in different human tumor cell lines by anti‑DEspR mAbs. a FACs analysis of different 
cancer tissue type CSCs: glioblastoma, triple negative breast cancer (TNBC), non‑small cell lung cancer (NSCLC), and pancreatic ductal adenocar‑
cinoma (PDAC) using AF‑568 labeled murine anti‑DEspR mAbs compared with AF568‑IgG2b murine isotype control. In Panc1 CSCs, low and high 
DEspR + CSCs are detected. b Multiple murine anti‑DEspR mAbs (5g12e8, 7c5b2, 6g8g7) inhibit CSC growth in suspension culture determined 
by the number of live CSCs after 5 days of incubation with murine anti‑DEspR mAbs, compared with corresponding control non‑treated CSCs. 
Comparative analysis is presented using % change from respective controls; ***, One Way ANOVA with Tukey’s multiple comparisons test P < 0.0001. 
Epitope 1 murine mAbs: 5g12, 5g12e8, 7c5, 7c5b2; Epitope 2 murine mAbs: 6g8, 6g8e8
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specific for different epitopes substantially fulfill UNI-
PROT criteria for determining a protein’s existence at 
the highest level such as detection of protein by antibody, 
demonstration of protein–protein interactions, demon-
stration of post-translational modifications, and demon-
stration of protein functionality [8].
Pull-down protein analysis experiments confirm the 
existence of DEspR via direct detection of the protein in 
human tumor cells by Western blot analysis of DEspR 
using multi-epitope anti-DEspR mAbs. The detection 
of the identical protein band by Western blot ‘walking’ 
with distinct anti-DEspR mAbs targeting two different 
epitopes, 5g12e8 mAb binding to DEspR epitope-1 that 
spans a splice junction, and 6g8g7 binding to DEspR 
epitope 2 that spans tryptophan[TGG]-codon#14, dem-
onstrate the existence of the DEspR protein. If the stop 
codon were indeed present at codon#14 instead of tryp-
tophan, there would simply be a 13 amino acid peptide 
with 1.5 kDa MW rather than the glycosylated 17.5 and 
12.5 kDa protein bands, or the non-glycosylated DEspR-
sequence predicted ~10 kDa protein.
Moreover, if there were indeed a stop codon at 
codon#14, DEspR would not be glycosylated nor inter-
nalized as the consensus sequence motifs for these sites 
are beyond the reported stop codon#14. The detection 
of the identical-sized protein on Western blot analysis of 
DEspR-positive Cos1 cell permanent transfectants and 
U87 tumor cells corroborates the protein product of the 
Fig. 5 Representative time series of internalization of fluorescently labeled (AF568) anti‑DEspR 7c5b2‑mAb by Panc1 tumor cells within 1.5 h.  
a Confocal images showing representative Panc1 tumor cells from baseline (t‑0) prior to addition of AF568‑labeled antibody, up to 1 h, 15 min from 
addition of AF568‑7c5b2 mAb. Increasing intracellular fluorescence (white) is detected in multiple Panc1 cells. b Higher magnification of Panc1 
tumor cells at baseline and t‑75 min with corresponding bright field images of Panc1 cells. At t‑60 min, representative image of Panc1 tumor cells 
exposed to control AF568‑labeled IgG2b isotype, with DAPI stained nuclei (blue) to mark cells, demonstrate no intracellular AF568 fluorescence (red) 
uptake. Bar = 20 microns
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transfected plasmid DEspR mini-gene construct previ-
ously reported, and corroborates splicing of the unspliced 
DEspR cDNA mini-gene construct [2].
Detection of DEspR by Western blotting but not by mass 
spectrometry analysis
We note that although DEspR was detected consistently 
in denatured conditions via Western blot analysis of 
membrane protein pull-down products using 5g12e8 and 
6g8g7 anti-DEspR mAbs, MS did not detect DEspR-spe-
cific peptides. However, non-detection by MS does not 
negate DEspR protein existence for several reasons. First, 
based on deduced amino acid sequence predicting a sin-
gle transmembrane integral membrane ~10 kDa protein 
that is glycosylated to 17.5/12.5  kDa, non-detection by 
peptide mass fingerprinting methods using techniques 
such as MALDI-TOF MS analysis is not surprising given 
that only 204 integral membrane proteins were detected 
on mass spectrometry in a study of rat endothelial cells 
at the National Center for Proteomics Research, and 
that no VEGF receptor-2 (151 kDa) was detected in this 
study [17]. Using 6718 as total number of membrane pro-
teins [18], Mirza et  al. [17] detected 3  % integral mem-
brane proteins on MS, while Peng et  al. [19] detected 
301 integral membrane proteins via SDS-PAGE shotgun 
proteomics or 4.5  % of 6718 total membrane proteins, 
and highest count using SCX-RPLC-MS/MS (MudPIT) 
strategy detected 876 integral membrane proteins or 
13 % of 6718 integral membrane proteins in murine NK 
cells [20]. Notably, of the ones detected by MS using an 
improved method that detects more membrane proteins 
using a centrifugal proteomic reactor, all the proteins 
detected were >150 kDa and ≥2 transmembrane domains 
[15].
Other factors could also account for non-detection 
by MS with current methodologies. As stated by Bensa-
lem et al. [21], peptide mass fingerprinting of membrane 
proteins, using techniques such as MALDI-TOF MS, 
remains a significant challenge for at least three reasons: 
(1) membrane proteins are naturally present at low levels, 
(2) many detergents strongly inhibit proteases and have 
deleterious effects on MALDI spectra, and (3) despite 
the presence of detergent, membrane proteins are unsta-
ble and often aggregate [21]. Additionally, glycosylation 
of DEspR also impedes current proteomic detection as 
reported by Cao et al. [16] stating that “deglycosylation of 
plasma membrane proteins by treatment with PNGase-
F did not yield detection of additional hydrophobic 
proteins”. Therefore, peptide mass fingerprinting MS 
analysis of PNGase-treated pull-down proteins which 
did not identify DEspR does not negate the existence of 
DEspR protein. These observations by others account for 
the non-detection by MS of the single transmembrane 
receptor  <150  kDa DEspR protein, thus excluding MS 
non-detection as counter evidence for the existence of 
DEspR protein, especially given multiple other experi-
mental evidence that fulfill UNIPROT criteria for deter-
mining a protein [8].
Demonstration of protein interactions, protein‑specific 
properties and functionality
Aside from ligand-specific activated DEspR signaling [3], 
detection of DEspR-protein interactions in the DEspR-
Galectin-1 complex, along with other pull-down protein 
partners, complies with a UNIPROT criterion for ascer-
taining existence of a protein as a gene product through 
the demonstration of protein-interactions [8]. The dis-
tinct functionality of DEspR vs Galectin-1 in terms of 
anoikis resistance indicates DEspR protein-specific func-
tions, rather than the potential counter-argument that 
DEspR functionality is merely due to the known Galec-
tin-1 functions.
More specifically, DEspR-specific inhibition by block-
ing antibodies induces anoikis in four cancer tissue type 
CSCs, corroborating earlier observations for Panc1 and 
U87 CSCs [3]. In contrast, Galectin-1 is pro-anoikis 
[22]. Given these two observations, we hypothesize that 
glycosylated DEspR plays a role in anoikis resistance by 
binding to Galectin-1 and inhibiting its pro-anoikis func-
tion, much like glycosylation of p16-INK4a de-induces 
Galectin-1 pro-anoikis functions through upregulation of 
Galectin-3 [22]. Confirmation of the DEspR-Galectin-1 
complex is demonstrated by co-localization on double-
immunostaining experiments, thus further strength-
ening evidence for translatability and functionality by 
the detection of protein–protein interactions following 
UNIPROT criteria [8]. Distinguishing the DEspR protein 
band by size and quantity from its pull-down partners 
identified from MS by their corresponding antibodies in 
serial sequential probing of the identical western blot, 
corroborates their detection by MS, as well as eliminates 
the potential of erroneous cross-reactivity pull-down 
results.
More importantly, given that demonstration of protein 
functionality certifies a protein’s existence [7, 8], the dem-
onstration of DEspR expression in >50 % of CSCs in four 
different cancer tissue types by FACS analysis and DEspR 
functionality via blocking antibody inhibition of CSC 
growth in all four different cancer tissue type CSCs—
glioblastoma, triple negative breast cancer, non-small cell 
lung cancer and pancreatic ductal adenocarcinoma, pro-
vide compelling evidence of the existence of DEspR pro-
tein based on UNI-PROT criteria and standards in the 
field [7, 8].
Furthermore, the demonstration of internalization of 
DEspR protein via live cell imaging is consistent with a 
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consensus internalization recognition sequence down-
stream to amino acid#14. This not only confirms translat-
ability of the DEspR protein beyond 13 amino acids, thus 
refuting the stop codon presence, but also demonstrates 
a protein-specific property, i.e. receptor internaliza-
tion and expands DEspR’s multi-functionality. Concord-
antly, these new data on functionality are supported by 
previous findings of DEspR roles in tumor angiogenesis, 
invasiveness, growth, as well as CSC survival in adverse 
conditions [3].
Conclusions
Altogether, in the context of an error prone site at 
codon#14, multiple protein assays independently and col-
lectively demonstrate the existence of the DEspR protein, 
and analyses that show DEspR protein properties (pro-
tein–protein interactions, glycosylation, internalization) 
and functional roles in multiple cancer tissue type CSCs, 
collectively certify the DEspR protein based on multi-
ple UNIPROT criteria and demonstrate that the human 
DEspR gene is not a pseudogene. Given that fulfillment 
of a single UNIPROT criterion for a protein’s existence is 
sufficient, fulfillment of multiple criteria present compel-
ling experimental evidence, at the highest protein level, 
that functional human DEspR protein exists.
Methods
Maxam–Gilbert sequencing
We performed Maxam–Gilbert sequencing essentially as 
described [23]. The hDEspR cDNA was 5′-end labelled 
with polynucleotide kinase using gamma-32P ATP. Chem-
ical treatments for Guanine (G), Guanine  +  Adenine 
(G + A), Cytosine + Thymine (C + T) and Cytosine (C) 
cleavages were done as described [23]. Cleavage products 
from the four reactions were size separated by 8 % dena-
turing polyacrylamide gel electrophoresis and fragments 
visualized by autoradiography. Electrophoresis was per-
formed at three different fixed wattages: 25 watts (#1), 35 
watts (#2) and 50 watts (#3).
Cell lines and antibody development and characterization 
by ELISA
Verified glioblastoma U87 MG (cat# ATCC HTB-14), 
triple negative breast cancer MDA-MB-231 (cat# ATCC 
HTB-26), non-small cell lung cancer NCI-H460 (cat# 
ATCC HTB-177) and pancreatic cancer Panc-1 (cat# 
ATCC CRL-1469) cell lines were obtained from ATCC. 
Isolation and propagation of U87, MB-231, H460 and 
Panc1 cancer stem cell-like cells (CSCs) was done as 
described [3]. CSCs were maintained and expanded 
through passage-5 in complete MammoCult® medium 
(Stem Cell Technologies, BC, Canada) containing 0.5  % 
Methylcellulose (Stem Cell Technologies, BC, Canada) in 
100 mm ultra-low attachment plates in 5 % CO2 humidi-
fied incubator at 37  °C. Testing for increased tumori-
genicity was performed in vivo at passage-5. Monoclonal 
antibody development was custom performed by Pro-
Mab Biotechnologies (Richmond, CA). For 7c5b2 [3] 
and 5g12e8 mAbs we used a nine amino-acid peptide, 
M1TMFKGSN E9 at the amino-terminal end of hDEspR 
[2] and a ten amino-acid peptide, E9MKSRWNWGS18, 
for 6g8g7 mAb as antigens respectively. Screening of 
hybridoma supernatants and characterization of mono-
clonal antibodies were performed by ELISA using corre-
sponding antigenic peptides. Serial dilutions of primary 
antibodies were incubated at 37  °C for 1  h. The wells 
were then incubated with horse radish peroxidase (HRP)-
labeled anti-IgG (Sigma) at 37 °C for 1 h. Reactions were 
analyzed at 450 nm after addition of 3,3′5,5′-tetrameth-
ylbenzidine substrate at 37 °C for 10 min.
Magnetic bead immunoprecipitation (pull‑down) of DEspR 
protein‑complex
U87 CSC membranes, Cos1-hDEspR permanent cell 
transfectant membranes and U87 xenograft tumor (in 
nude rats) membranes were isolated by differential 
centrifugation as described [2]. Antibody coupling to 
magnetic Dynabeads M-450 Epoxy (Invitrogen) was per-
formed as per manufacturer’s instructions using 200 μg 
of anti-hDEspR 5g12e8 mAb per 1 mL of beads (4 × 108 
beads). For target binding 100  μL of 5g12e8-coupled 
beads (4  ×  107 beads) and 1.3  mg membrane protein 
were incubated for 2 h at 4 °C in 1 ml ice-cold PBS con-
taining 2 mM EDTA. To capture mAb-bound protein, the 
tube was placed in a magnet for 2 min, the supernatant 
discarded and the beads washed five times with 1  mL 
PBS buffer containing 2 mM EDTA and 0.2 % Tween-20 
at room temperature. This washed magnetic bead-‘pull-
down’-protein complex was then analyzed using different 
methods. (a) For SDS-PAGE (18  % polyacrylamide) the 
beads were resuspended in 20 µL of 1X Laemmle sample 
buffer and proteins denatured at 65 °C × 30 min in order 
to size-separate and assess size(s) of protein(s) ‘pulled-
down’. (b) For PNGase F (SIGMA) treatment of pull-
down proteins to assess glycosylation states of proteins 
pulled-down, the beads were resuspended in 20 μL of a 
buffer containing 20 mM ammonium bicarbonate pH 8.0, 
1 % SDS, 100 mM beta-mercaptoethanol and incubated 
for 30 min at 65 °C. The tube was then placed in a magnet 
for 2 min. The supernatant was collected to which 20 μL 
of 0.25 M KCl was added to eliminate SDS by precipita-
tion. To lower KCl concentration the supernatant (40 μL) 
was collected, diluted 10X with 20  mM ammonium 
bicarbonate pH 8.0 and concentrated by using a Micro-
con YM-3 centrifugal filter (Millipore). The concentrated 
sample was treated with PNGase F (2.5 units) in a final 
Page 12 of 14Herrera et al. BMC Molecular Biol  (2016) 17:15 
volume of 20 μL for 3 h at 37 °C. Gels were stained either 
with QC Colloidal Coomassie Stain (Bio-Rad) or Silver 
(BioRad Silver Stain Plus Kit) following manufacturer’s 
instructions.
Western blot analysis
Western blot analysis was done essentially as described 
[2] using pull-down proteins extracted from 2  ×  107 
5g12e8-coupled Dynabeads. Serial Western blot analyses 
of proteins pulled down—hDEspR, hGalectin-1, hRab-
1b and hTMED10—were done sequentially by stripping 
and re-probing the same blot in the following order: 1st, 
human-specific DEspR mAb (5g12e8 40  μg/ml, second-
ary anti-mouse IgG at 1:20,000), 2nd, Rab-1b polyclonal 
antibody (pAb) (Santa Cruz Biotechnology, cat # sc-599, 
at 1  μg/ml, secondary anti-rabbit IgG at 1:20,000), 3rd, 
human-specific Galectin-1 (Abcam, cat # ab25138 at 
0.4  μg/ml, secondary anti-rabbit IgG 1:20,000) and 4th, 
pAb TMED10 (Abcam, cat # ab72666, at 10 μg/ml, sec-
ondary anti-rabbit IgG 1:20,000).
Serial Western blot analyses of U87 tumor cell mem-
brane and Cos1-hDEspR cell membrane pull-downs were 
done sequentially by stripping and re-probing the same 
blot in order: 1st, hDEspR mAb (5g12e8 40  μg/ml, sec-
ondary anti-mouse IgG at 1:20,000) and then 2nd, hGa-
lectin-1 (Abcam, cat#ab25138, at 0.4  μg/ml, secondary 
anti-rabbit IgG 1:20,000).
Serial western blot of U87 tumor membrane pull-down 
was also reacted sequentially by stripping and re-probing 
the same blot using first the following in order: 1st, hDE-
spR mAb (6g8g7 40 μg/ml, secondary anti-mouse IgG at 
1:20,000), and 2nd, hDEspR mAb (5g12e8 40 ug/ml, sec-
ondary anti-mouse IgG at 1:20,000).
Immunoreactive proteins were detected by chemi-
luminescence using the ECL Western Detection kit (GE 
Healthcare) as per manufacturer’s specifications.
Mass spectrometry analysis
Mass spectrometry of pull-down proteins was custom-
performed by Creative Proteomics (Shirley, NY). Briefly, 
proteins were reduced for 40  min with 5  mM dithi-
othreitol in 25  mM NH4HCO3 at room temperature 
and alkylated for 40 min with 15 mM iodoacetamide in 
25 mM NH4HCO3 in the dark. After washed and dehy-
drated, the alkylated samples were digested overnight at 
37  °C with trypsin in a 1:50 enzyme-to-substrate ratio 
(Promega, V5113). Following digestion, the peptide mix-
tures were acidified with trifluoroacetic (TFA) to 1 %, and 
desalted by home-made C18 tips. Finally, the desalted 
peptide samples were dried and dissolved in 10  μL of 
0.1 % formic acid in water and subjected to nanoLC-MS/
MS analysis in a Q Exactive mass spectrometer. The raw 
MS files were analyzed and searched against Uniprot 
human protein sequence database using Proteome Dis-
coverer 1.4 (Thermo Fisher Scientific, USA). The param-
eters were set as follows: the protein modifications were 
carbamidomethylation (C) (fixed), oxidation (M) (vari-
able), and myristyl on glycine (variable), Asn to Asp 
(variable); the enzyme specificity was set to trypsin; the 
maximum missed cleavages were set to 2; the precursor 
ion mass tolerance was set to 10 ppm, and MS/MS toler-
ance was 0.6 Da.
Immunofluorescence analysis of subQ xenograft U87‑CSC 
tumors
Double immunofluorescence staining was done as 
described [3]. Human-specific anti-DEspR mAb (5g12e8) 
and human-specific anti-Galectin-1 antibody (Abcam, 
cat#ab25138) were labeled with AlexaFluor(AF)-488 or 
AF568, and used at 1  μg/ml for anti-Galectin-1 and at 
100 μg/ml for 5g12e8 mAbs on fixed, paraffin-embedded 
sections following antigen-retrieval. Digital photomi-
croscopy was done using a Zeiss Axioskop fluorescence 
microscope with auto-exposure settings.
FACS analysis of U87‑CSCs, MB‑231‑CSCs, H460‑CSCs 
and Panc1‑CSCs
U87-CSCs, MB-231-CSCs, H460-CSCs and Panc1-CSCs 
were incubated in ice-cold Hank’s balanced salt solution 
(HBSS, Invitrogen, NY) plus 2 % FBS containing: (a) 10 μg/
ml AF-568 labeled 7c5b2 mAb, or (b) 10  μg/ml AF-568 
labeled IgG2b as isotype control. Duplicate samples were 
incubated for 20 min at 4 °C, washed, resuspended in 1 % 
FBS/HBSS, 1 % PFA, filtered and analyzed on an LSR-II-
FACS instrument. Analysis was done using FloJo Flow 
Cytometry Analysis Software (http://www.FloJo.com).
DEspR‑inhibition of CSC‑growth
DEspR-inhibition studies were performed as described 
[3]. CSCs (2000/well) were seeded in ultra-low attach-
ment 96-well plate and treated with different blocking 
anti-hDEspR mAbs (5g12e8, 7c5b2 and 6g8g7) at 100 μg/
ml, compared with control non-treated CSCs with six 
replicates for each. CSCs were cultured in optimal (5 % 
CO2, humidified incubator at 37  °C) non-adherent con-
ditions. Anti-hDEspR (5g12e8, 7c5b2 and 6g8g7) mAbs 
were added at seeding, day-2 and day-4. Live and dead 
CSCs were counted using Trypan Blue on day-5.
RNA sequence analysis
The NCBI Sequence Read Archive was searched on 
7/17/2013 with a query sequence provided by the Gen-
bank accession for “Homo sapiens dual endothelin-
1(VEGFsp)/angiotensin II receptor (DEAR) mRNA, 
complete cds,” gi|144,954,325|gb|EF212178.1|, against 
727 sequencing runs (Additional file 5).
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Live cell imaging
Fluorescence and transmitted light images were acquired 
with a Zeiss LSM 710 Duo confocal microscope (Carl Zeiss, 
Thornwood NY). Excitation was from a 561 nm DPSS laser. 
A 63X 1.4 NA planapochromat oil immersion objective 
was used. The cells were in 35 mm dishes with coverglass 
bottoms. Emission was collected from 575–725 nm. Cells 
were maintained under physiological conditions using a 
Pecon stage-top incubation system which maintained 37° 
centigrade and 5 % CO2. Analysis was done using Image J 
(Image J, Wayne Rasband, NIH) with identical settings for 
brightness and contrast adjustments for all images. Live 
cell imaging with AF-568 labeled isotype IgG2b control 
was performed in identical conditions. At 60  min, cells 
were fixed briefly and mounted with Vectashield mount-
ing medium with DAPI (Vector Laboratories, CA, Cat.# 
H-1200). Photomicroscopy was done using a Zeiss Axi-
oskop fluorescence microscope (Carl Zeiss, Thornwood 
NY) with differential interference contrast (DIC).
Statistical analysis
All data were analyzed for normality and descriptive 
statistics. The following statistical tests were performed 
using SigmaPlot 11.0 or PRISM 5: one-way analysis of 
variance (ANOVA) followed by Tukey multiple compari-
sons test (MCT) for CSC-growth inhibition experiments. 
A P < 0.05 was considered statistically significant.
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